التفاصيل البيبلوغرافية
| العنوان: |
PET‐adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH‐05 trial |
| المؤلفون: |
Pavlovsky, Astrid, Fernandez, Isolda, Kurgansky, Nicolas, Prates, Virginia, Zoppegno, Lucia, Negri, Pedro, Milone, Gustavo, Cerutti, Ider, Zabaljauregui, Soledad, Mariano, Romina, Grecco, Horacio F., Basquiera, Ana L., Saba, Silvia, Rudoy, Silvia, Sackmann, Federico, Castano, Vanesa, Remaggi, Guillermina, Cabrejo, Maria, Roveri, Eriberto, Casale, Maria F., Cabane, Vanina, Taus, Rossana, Venturini, Claudia, Sakamoto, Francisco, Varela, Ana I., Riddick, Maximiliano, Pavlovsky, Santiago |
| المصدر: |
British Journal of Haematology ; volume 185, issue 5, page 865-873 ; ISSN 0007-1048 1365-2141 |
| بيانات النشر: |
Wiley |
| سنة النشر: |
2019 |
| المجموعة: |
Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: |
Summary The role of Ann Arbor staging in determining treatment intensity after achieving a negative positron emission tomography ( PET ) has not been established in classical Hodgkin lymphoma ( cHL ). Patients with stage I– IV cHL , received three cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and an interim PET scan ( PET 3). PET 3‐negative patients received no further therapy. PET 3‐positive patients received three additional cycles of ABVD plus involved‐field radiation therapy or salvage chemotherapy, if refractory to ABVD , and were re‐evaluated by PET scan ( PET 6). Study endpoints were 3‐year progression‐free survival ( PFS ) and overall survival ( OS ) rates. Two hundred and thirty‐nine patients with early‐stage and 138 with advanced‐stage were evaluable. Overall, 260 patients (70%) were PET 3‐negative and had higher 3‐year PFS (90% vs. 65%; P < 0·0001) and OS (98% vs. 92%; P = 0·007) rates than PET 3‐positive patients. All PET 3‐negative patients, regardless of disease stage at diagnosis, achieved similarly good PFS (90–91%; P = 0·76) and OS (97–99%). The only independent prognostic factor for PFS was PET 3‐negativity (Hazard ratio 3·8; 95% confidence interval 2·4–6·3; P < 0·0001). This study suggests that cHL patients who achieve a negative PET 3 following ABVD have an excellent outcome, regardless of stage at diagnosis. An appropriately powered, phase III trial will be necessary to confirm these findings. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1111/bjh.15838 |
| الإتاحة: |
https://doi.org/10.1111/bjh.15838Test |
| حقوق: |
http://onlinelibrary.wiley.com/termsAndConditions#vorTest |
| رقم الانضمام: |
edsbas.A772DDD8 |
| قاعدة البيانات: |
BASE |
